Tango Therapeutics (NASDAQ:TNGX) Given New $20.00 Price Target at Guggenheim

Tango Therapeutics (NASDAQ:TNGX) had its price objective upped by Guggenheim from $18.00 to $20.00 in a research report released on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

A number of other research analysts have also recently weighed in on the stock. Piper Sandler boosted their price objective on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. HC Wainwright raised their target price on shares of Tango Therapeutics from $13.00 to $27.00 and gave the stock a “buy” rating in a report on Friday. Wolfe Research assumed coverage on shares of Tango Therapeutics in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. Wall Street Zen upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Finally, B. Riley Financial increased their price objective on shares of Tango Therapeutics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock opened at $16.95 on Friday. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -19.48 and a beta of 1.76. The stock has a 50 day moving average price of $11.86 and a 200-day moving average price of $9.44. Tango Therapeutics has a one year low of $1.03 and a one year high of $17.63.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 66.01% and a negative net margin of 151.15%. Sell-side analysts predict that Tango Therapeutics will post -1.19 earnings per share for the current fiscal year.

Insider Transactions at Tango Therapeutics

In other news, insider Adam Crystal sold 54,345 shares of Tango Therapeutics stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total transaction of $693,985.65. Following the completion of the sale, the insider directly owned 132,873 shares in the company, valued at approximately $1,696,788.21. This trade represents a 29.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the sale, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 113,633 shares of company stock worth $1,420,857. 7.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tango Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. CWM LLC grew its stake in Tango Therapeutics by 182.2% in the 2nd quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after acquiring an additional 3,167 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of Tango Therapeutics during the fourth quarter valued at approximately $35,000. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares during the period. Legal & General Group Plc boosted its holdings in shares of Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after purchasing an additional 1,640 shares during the period. Finally, Ameritas Investment Partners Inc. grew its stake in Tango Therapeutics by 78.8% in the second quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock worth $40,000 after purchasing an additional 3,452 shares in the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: Clinical collaboration with Erasca to test ERAS‑0015/vopimetostat in MTAP‑deleted, RAS‑mutant cancers expands Tango’s clinical footprint and creates near‑term partnership newsflow that likely drove buying interest and record highs. TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
• Positive Sentiment: HC Wainwright sharply raised its price target to $27 (buy), a large explicit upside that can boost sentiment and buy‑side conviction. HC Wainwright price target raise
• Positive Sentiment: Guggenheim raised its target to $20 and reiterated a buy rating, adding to analyst momentum and supporting the share‑price lift. Guggenheim price target raise
• Positive Sentiment: Wedbush raised its target to $19 with an “outperform” rating, another vote of confidence from sell‑side analysts that can attract new buyers. Wedbush price target raise
• Positive Sentiment: An investment firm added ~1.1M shares (~$9.5M), increasing its reported position materially — institutional buying that signals conviction and can underpin the rally. Investment Firm Bets Big on TNGX Stock
• Neutral Sentiment: Quarterly results beat EPS estimates by $0.02 (reported -$0.29 vs. -$0.31) — a modest positive but company remains unprofitable with negative margins and ROE, so financials are unlikely to change valuation narrative immediately. Tango Therapeutics press release
• Negative Sentiment: A Seeking Alpha piece warns against buying into the rally despite PRMT5 promise, highlighting clinical, competitive and valuation risks that could limit upside or prompt pullbacks if trial data or execution falter. Tango Therapeutics: I’m Not Buying Into Latest Rally

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.